



Anticancer and antibacterial activities of embelin: micro and nano aspects

Mehran Alavi^{1,2*}, Fleming Martinez³, Daniel R. Delgado⁴, Darío A. Tinjacá⁵

¹Department of Biological Science, Faculty of Science, Kurdistan University, Sanandaj, Kurdistan, Iran

²Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran

³Department of Pharmacy, Faculty of Sciences, Universidad Nacional de Colombia, South America, Colombia

⁴GRIAUCC Research Group, Department of Engineering, Universidad Cooperativa de Colombia, Neiva, Huila, Colombia

⁵Facultad de Ciencias, Universidad El Bosque, Bogotá D. C., Colombia

ARTICLE INFO

Review paper

Article history:

Received: 18 May 2022

Accepted: 13 June 2022

Published: 14 June 2022

Keywords:

Poor solubility, Bioavailability, Functionalized nanomaterials, Biocompatible polymeric nanoparticles, Efflux pump, Multidrug-resistant bacteria

ABSTRACT

There are some reported anticancer and antibacterial effects for embelin, although, its poor aqueous solubility and bioavailability are main hindrance to apply embelin in therapeutics. In this regard, nanoformulations based on bare or functionalized nanomaterials can overcome these disadvantages. Embelin can be loaded or incorporated in biocompatible polymeric or protein nanoparticles (NPs) such as albumin NPs for improvement of solubility. In addition, targeting specific active sites of some major biological components such as amino acids of efflux pump in multidrug-resistant (MDR) bacteria can be possible by nanoformulation of embelin. The induction of apoptosis processes in cancer cells is also one of the major anticancer mechanisms of embelin, which has exhibited significant *in vitro* and *in vivo* results when nanoformulations are employed. The main aim of this review is to make a discussion about the advantages of these new nanoformulations in comparison with pure embelin. Overlay, embelin may be loaded or incorporated in biocompatible protein or polymeric NPs such as albumin NPs. Specifically, for antibacterial activity, nanoformulation of embelin-loaded chitosan Au-NPs with ciprofloxacin antibiotic exhibited the efficient interactions between embelin and the active sites of the efflux pump. Additionally, hyaluronic acid-coated amphiphilic polymeric NPs have the ability to enhance embelin uptake by triple negative breast cancer cells.

DOI:

Copyright: © 2022 by the MNBA.

Introduction

Anticancer and antibacterial activities of various natural materials based on micro and nano formulations have been reported in recent years [1-10]. Specifically, a large class of quinones can be found in a wide range of organisms including in arthropods, plants, and bacteria (Figure 1a-k). Redox, antimicrobial, antifertility, anthelmintic, analgesic, anti-inflammatory, antihelmintic, analgesic, antitumor, and antioxidant activities have been found for embelin (C₁₇H₂₆O₄, 2,5-dihydroxy-3-undecyl-1,4-benzoquinone, preferred IUPAC name: 2,5-Dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione, CAS number: 550-24-3, PubChem CID: 3218, molar mass: 294.39 g·mol⁻¹) as a herbal para-benzoquinone derived from general quinones (Figure 1k), which can be extracted from dried berries of *Embelia ribes*, medicinal plant species used in traditional medicine of China and India [11].

The replacement of the C-11 alkyl chain by other aryl, benzyl, and/or alkyl groups is the common way for preparation of the embelin derivatives [12].

Generally, there are various materials (Figure 2) [13] and methods (Figure 3A) for fabrication and functionalization of nanomaterials (NMs), particularly metal or metal oxide nanoparticles (NPs), with different physicochemical properties (Figure 3B) [14]. Embelin metabolite has the ability to form complexes with metals resulting from their antioxidant property, which make this metabolite desirable to synthesize and modify NMs specifically noble metal NPs. These complexes can have synergistic therapeutic effects as anticancer and antibacterial activity both *in vivo* and *in vitro* [15-17]. Moreover, other organic and inorganic NMs may be used to nanoformulate embelin. Therefore, in this review, we have tried to discuss these activities with related challenges such as the poor aqueous

*Corresponding author. E-mail: mehranbio83@gmail.com

solubility and bioavailability of embelin, according to recent studies. In contrast to a previous review, micro and nano formulations of embelin have been presented and compared in order to obtain a suitable approach of future investigations.




Fig. 1. Molecular structures of some quinones involving a) 2,3,5,6-Tetrachloro-parabenzoquinone or chloranil, b) 1,2-Benzoquinone, c) 1,4-Benzoquinone, d) 1,4-Naphthoquinone, e) 9,10-Anthraquinone, f) 1,2-dihydroxyanthraquinone or alizarin, g) daunorubicin, h) 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone or DDQ, i) gentisyl-quinone-isovalerate or blattellaquinone, j) lawsone, and (k) embelin (<https://pubchem.ncbi.nlm.nih.gov>).




Fig. 2. Common materials suitable for fabrication of noble metal NPs [13].




Fig. 3. (A) Various approaches for synthesis of NMs and (B) different physicochemical properties of NMs [14].

Micro aspects

Anticancer activity

In cancer tumor cells, many deregulated cellular processes can be regulated by casein kinase II (CK2) with the functions of changing cellular morphology as well as promotion of angiogenesis cell growth, cellular transformation, cell survival, and cell proliferation [18-20]. Therefore, targeting this

protein is critical to hinder cancer cells, wherein two drugs of CX-4945 (an ATP competitive CK2 inhibitor) and CIGB-300 (a peptidic inhibitor) showed acceptable inhibition in clinical trials [12, 21, 22]. Various derivatives of embelin were evaluated against CK2, for instance 4I (2-(tert-butylamino)-3-(furan-3-yl)-5-hydroxy-6-undecyl benzofuran-4,7-dione) as an ATP competitive CK2 inhibitor showed IC_{50} value of 0.63 μ M against MCF7 cells, metastatic adenocarcinoma isolated from the breast tissue. Moreover, molecular docking studies confirmed the role of the C-11 alkyl chain in the orientation of this derivative of embelin to get suitable interaction [12]. Embelin has the potential ability to hinder X-linked inhibitor of apoptosis protein (XIAP; inhibitor of apoptosis protein 3) and NF- κ B (nuclear factor kappa B), a protein that controls cell survival [23]. Additionally, in the case of breast cancer cell lines including MDA-MB-453, MDA-MB-231, and MCF-7, embelin has the ability to downregulate cellular FADD-like IL-1 β -converting enzyme inhibitory protein (cFLIP), and thus, facilitating anti-tumor activity of IL-1 β -stimulated human umbilical cord mesenchymal stem cells [24].

Antibacterial activity

There is a plethora of embelin derivatives having antibacterial activity towards various Gram-negative and Gram-positive bacteria. For different dihydropyran and dihydropyridin derivatives of embelin, GI_{50} (concentration that inhibit growth of 50% of bacteria) was in the range of 1.8-35.1 μ M, 1.3-35.9 μ M, and 5.7-55 μ M against of *S. aureus* ATCC25923, *S. aureus* NRS402, and *E. faecalis* ATCC29212, respectively. Among these derivatives, 9-(3,4-Methylenedioxyphenyl)-2-hydroxy-6,6-dimethyl-3-undec-yl-5,6,7,9-tetrahydroxanthene-1,4,8-trione exhibited more antibacterial activity against *S. aureus* NRS402 compared to other derivatives [11]. In similar study, in comparisons with three antibiotics including oxacillin, vancomycin, and mupirocin with minimum inhibitory concentration (MIC) of <1 μ g/mL, there were MIC ranges of 1 up to >128 μ g/mL and 4 up to >128 μ g/mL, respectively against *S. aureus* NRS402 and *S. aureus* ATCC25923 for various dihydropyran embelin derivatives. For two bacteria, cis adduct of

(±)-11-Chloro-2-hydroxy-6,6-dimethyl-3-undecyl-6a,7-dihydrochromeno[3,4-c]chromene-1,4(6H,12bH)-dione displayed significant antibacterial activity [25]. Formulation of embelin in conventional ointment is an attractive strategy particularly in large scale. A combination of embelin, emulsifying wax, white soft paraffin, and liquid paraffin in concentrations of 3, 27, 50, and 20 % was used to hinder *S. aureus*, *S. epidermidis*, *E. coli*, and *P. aeruginosa*. 50 mg/mL concentration of modified ointment illustrated 9.33, 8.67, 9.67, and 12 mm inhibition zone diameters (IZDs) towards *S. aureus*, *S. epidermidis*, *E. coli*, and *P. aeruginosa*, respectively [26]. Fliiranylidene benzofuranone and 1,4-dibenzo furandione can be prepared from the irradiation of embelin under microwave oven for 6 min, wherein IZDs of 9, 9, 7, and 7 mm were found for these compounds against *E. coli*, *P. aeruginosa*, *B. subtilis*, and *S. aureus* [27]. In another study, MIC range for three strains of *S. aureus* ATCC25923, *S. aureus* NRS402, and *E. faecalis* ATCC29212 were 1- >128 µg/mL, <1- >128 µg/mL, and 1- >128 µg/mL, respectively. Excellent antibacterial activity was observed for 10-(4-bromophenyl)-8-hydroxy-3-methyl-7-undecylpyrano[4,3-b]chromene-1,6,9(10H)-trione towards *S. aureus* NRS402 with MIC value of <1 µg/mL [28].

Nano aspects

Anticancer activity

Paclitaxel is a commonly used chemotherapeutic drug to eradicate various types of cancers including pancreatic cancer, cervical cancer, ovarian cancer, lung cancer, esophageal cancer, Kaposi's sarcoma, and breast cancer [29]. A plethora of drug delivery nano-systems such as lipid NPs, cubosomes, liposomes, and micelles were evaluated to increase bioavailability and active targeting of tumor cells in physiological condition [30]. Polyethylene glycol (PEG) is a hydrophilic polymer with neutral charge, which is employed to augment bioavailability and hydrophilicity of therapeutic agents. Paclitaxel loaded PEG₃₅₀₀-derivatized embelin with the size range of 20–30 nm showed IC₅₀ of 13.5 ng/mL compared to neat paclitaxel with 65 ng/mL towards breast cancer cell line of MDA-MB-231 after 72 h incubation. Moreover, there was a very low hemolysis level for these formulations in comparison

with cationic polymer of polyethylenimine [31]. In a similar study, loading of paclitaxel by PEG₅₀₀₀-derivatized embelin at molar ratio of 1:1 (size of 21.7 nm and poly dispersity index (PDI) of 0.25) showed 13 % and 70.8 % of drug loading capacity and drug loading efficiency, respectively. In addition, this study illustrated complete hindrance of cancer growth in a model of human prostate cancer xenograft with a low toxicity to the animals [17]. Albumin protein having biocompatible and hydrophilic properties is an appropriate option for the embelin formulation in physiological conditions. According to a molecular docking study, free energy and binding constant values were observed as -5.1 kcal·mol⁻¹ and 5.9 (±0.1) × 10⁴ M⁻¹ at 25 °C, respectively. This complex formulated by hydrogen and hydrophobic bond interactions illustrated an induction of 26.3% of apoptosis for HeLa cell line with an IC₅₀ value of 29 µM [32]. Hyaluronic acid-coated amphiphilic polymeric NPs including pH-sensitive-polyethylenimine(PEI)-poly[(1,6-hexanediol)-diacrylate-β-5-hydroxyamylamine] (PBAE) have been used for co-delivery of APO2L or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) plasmid (pTRAIL), and embelin, against triple negative breast cancer, which is one the most complicated type of breast cancer. Enhanced embelin and APO2L uptake by MDA-MB-231 TNBC cells have been obtained because of the specific binding between hyaluronic acid and CD44 of MDA-MB-231 TNBC cells [33].

Antibacterial activity

There are various inorganic NPs including metal, metal oxide, and metalloid NPs, as well as some organic NPs like liposomes, cubosomes, and solid lipid NPs, suitable to nanoformulate antibiotics and/or natural metabolites with antibacterial activity [34-43]. High molar extinction coefficient, large absorption cross-section, and surface plasmon resonance (SPR) in the near infrared (NIR) range are the main properties of noble metal NPs specifically Ag and Au-NPs depending on size and shape, which make these NPs suitable for applications in photodynamic therapy, two-photon luminescence imaging, and surface enhanced Raman scattering [13, 44]. As the major antibacterial mechanisms, these NPs in combination with other natural

materials can produce reactive oxygen species (ROS), followed by the respective damaging on biological macromolecules, which in turn, could cause inhibition of the efflux pumps of bacteria [45]. As mentioned in the introduction section, embelin has the ability to form complexes with metal resulting from their antioxidant property, which can be helpful in biosynthesis of metal or metal oxide NPs. For example, plasmonic Ag-NPs with bimodal size distribution (~3 and 15 nm) and antibacterial activity against *S. aureus* and *E. coli* were stabilized by embelin. Antibacterial steps specifically in the case of smaller size of Ag-NPs (3 nm at 5 µg/mL) were attachment to cell membrane resulting from binding to thiol groups (-SH) and reduction of the disulfide bonds, disruption of membrane, and leakage of bacterial macromolecules, leading to damaging of biological macromolecules such as proteins and nucleic acids followed by shrinkage of bacteria [16]. The water solubility of embelin may be enhanced by formulation of this metabolite with some surfactant agents. In this way, self-nano-emulsifying drug delivery system containing Capryol 90 as oil, Acrysol EL 135 as surfactant and PEG 400 as co-surfactant provided suitable stability for 6 months and water solubility-increasing for encapsulation of embelin. After 6 months, three parameters of self-emulsifying time, globule size, and release of drug at 15 min were 22.98 sec, 30.22 nm, and 97.06 %, respectively [46]. Antibiotic-resistant bacteria are classified into three categories including MDR, extensively-drug resistant (XDR), and pan-drug resistant (PDR) according to the extent of antibiotic resistance [47]. One major way to escape from antibiotics in these types of bacteria is overexpression of efflux pumps in their envelope. According to a molecular docking study, involving formulation of embelin-loaded chitosan Au-NPs with ciprofloxacin, there were effective interactions between embelin and the active sites of the efflux pump related proteins in EC-r (TolC, AcrB, and AcrA) and PA-r (OprM, MexB, and MexA) [48]. As mentioned above, one of the main compatible NPs with readily solubility in water is albumin NPs, which can be employed to load or incorporate embelin as active ingredient. According to results of MTT assay (that involves the reduction of the tetrazolium dye MTT, chemically known as 3-(4,5-

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, to its insoluble derivative formazan, which has a purple color), embelin cross-linked albumin NPs at a high concentration of 1500 µg/mL displayed 95% cell viability for NIH3T3 and L929 cell lines [49].

Conclusions

The poor aqueous solubility and bioavailability of embelin can be improved by novel drug delivery systems based on NMs. For improvement of solubility, embelin can be loaded or incorporated in biocompatible polymeric or protein NPs such as albumin NPs. Moreover, in the case of MDR bacteria, one major way to escape from antibiotics is overexpression of efflux pumps in bacterial envelope. In this regard, nanoformulation of embelin-loaded chitosan Au-NPs with ciprofloxacin exhibited the efficient interactions between embelin and the active sites of the efflux pump related proteins in EC-r (TolC, AcrB, and AcrA) and PA-r (OprM, MexB, and MexA). Regarding the anticancer activity, hyaluronic acid-coated amphiphilic polymeric NPs can increase the embelin uptake by triple negative breast cancer cells. As a main conclusion, nanoformulation of embelin can overcome some disadvantages of this plant metabolite observed in physiological conditions. However, future studies should improve or optimize both micro and nano aspects of embelin formulation in the combination with other anticancer and antibacterial activities.

Study Highlights

- The aqueous solubility and bioavailability of embelin can be enhanced by nano drug delivery systems.
- Embelin can be loaded or incorporated in biocompatible polymeric NPs for improvement of its solubility.
- Optimizing both micro and nano aspects of embelin formulation to augment anticancer and antibacterial activities is indispensable.

Funding

This work was not supported by any institutes.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals or human participants.

Authors' contribution

MA: conceptualization, preparing the first draft, and revising; FM, DRD, and DAT: revising of the manuscript.

Acknowledgment

None.

References

1. dos Santos JFS, Tintino SR, de Freitas TS, Campina FF, de A. Menezes IR, Siqueira-Júnior JP, et al. In vitro e in silico evaluation of the inhibition of *Staphylococcus aureus* efflux pumps by caffeic and gallic acid. *Comparative Immunology, Microbiology and Infectious Diseases*. 2018;57:22-8. doi:<https://doi.org/10.1016/j.cimid.2018.03.001>
2. dos Santos JFS, Tintino SR, da Silva ARP, dos S. Barbosa CR, Scherf JR, de S. Silveira Z, et al. Enhancement of the antibiotic activity by quercetin against *Staphylococcus aureus* efflux pumps. *Journal of Bioenergetics and Biomembranes*. 2021;53(2):157-67. doi:<https://doi.org/10.1007/s10863-021-09886-4>
3. da Costa RHS, Rocha JE, de Freitas TS, Pereira RLS, Junior FNP, de Oliveira MRC, et al. Evaluation of antibacterial activity and reversal of the NorA and MepA efflux pump of estragole against *Staphylococcus aureus* bacteria. *Archives of Microbiology*. 2021;203(6):3551-5. doi:<https://doi.org/10.1007/s00203-021-02347-x>
4. dos Santos Barbosa CR, Scherf JR, de Freitas TS, de Menezes IRA, Pereira RLS, dos Santos JFS, et al. Effect of Carvacrol and Thymol on NorA efflux pump inhibition in multidrug-resistant (MDR) *Staphylococcus aureus* strains. *Journal of Bioenergetics and Biomembranes*. 2021;53(4):489-98. doi:<https://doi.org/10.1007/s10863-021-09906-3>
5. Alavi M, Adulrahman NA, Haleem AA, Al-Râwanduzi ADH, Khusro A, Abdelgawad MA, et al. Nanoformulations of curcumin and quercetin with silver nanoparticles for inactivation of bacteria. *Cellular and Molecular Biology*. 2022;67(5):151-6. doi:<https://doi.org/10.14715/cmb/2021.67.5.21>
6. Ahmadi S, Ahmadi G, Ahmadi H. A review on antifungal and antibacterial activities of some medicinal plants. *Micro Nano Bio Aspects*. 2022;1(1):10-7
7. Selyutina OY, Kononova PA, Koshman VE, Fedenok LG, Polyakov NE. The Interplay of Ascorbic Acid with Quinones-Chelators—Influence on Lipid Peroxidation: Insight into Anticancer Activity. *Antioxidants*. 2022;11(2):376. doi:<https://doi.org/10.3390/antiox11020376>
8. Silva Pereira RL, Campina FF, Costa MdS, Pereira da Cruz R, Sampaio de Freitas T, Lucas dos Santos AT, et al. Antibacterial and modulatory activities of β -cyclodextrin complexed with (+)- β -citronellol against multidrug-resistant strains. *Microbial Pathogenesis*. 2021;156:104928. doi:<https://doi.org/10.1016/j.micpath.2021.104928>
9. Doosti-Moghaddam M, Miri HR, Ghahghaei A, Haginegd MR, Saboori H. Effect of unripe fruit extract of *Momordica charantia* on total cholesterol, total triglyceride and blood lipoproteins in the blood of rats with hyperlipidemia. *Cellular, Molecular and Biomedical Reports*. 2022;2(2):74-86. doi:<https://doi.org/10.55705/cmbr.2022.338806.1038>
10. Ahmadi S. Antibacterial and antifungal activities of medicinal plant species and endophytes. *Cellular, Molecular and Biomedical Reports*. 2022;2(2):109-15. doi:<https://doi.org/10.55705/cmbr.2022.340532.1042>
11. Peña R, Jiménez-Alonso S, Feresin G, Tapia A, Méndez-Alvarez S, Machín F, et al. Multicomponent Synthesis of Antibacterial Dihydropyridin and Dihydropyran Embelin Derivatives. *The Journal of Organic Chemistry*. 2013;78(16):7977-85. doi:<https://doi.org/10.1021/jo401189x>
12. Oramas-Royo S, Haidar S, Amesty Á, Martín-Acosta P, Feresin G, Tapia A, et al. Design, synthesis and biological evaluation of new embelin derivatives as CK2 inhibitors. *Bioorganic Chemistry*. 2020;95:103520. doi:<https://doi.org/10.1016/j.bioorg.2019.103520>
13. Majeed SA, Sekhosana KE, Tuhl A. Progress on phthalocyanine-conjugated Ag and Au nanoparticles: Synthesis, characterization, and photo-physicochemical properties. *Arabian Journal of Chemistry*. 2020;13(12):8848-87. doi:<https://doi.org/10.1016/j.arabjc.2020.10.014>
14. Jeyaraj M, Gurunathan S, Qasim M, Kang M-H, Kim J-H. A Comprehensive Review on the Synthesis, Characterization, and Biomedical Application of Platinum Nanoparticles. *Nanomaterials*. 2019;9(12):1719. doi:<https://doi.org/10.3390/nano9121719>
15. Tellone E, Galtieri A, Barreca D, Ficarra S. Chapter 2.8 - Coenzyme Q10 and Embelin. In: Nabavi SM, Silva AS, editors. *Nonvitamin and Nonmineral Nutritional Supplements*: Academic Press; 2019. p. 69-73. doi:<https://doi.org/10.1016/B978-0-12-812491-8.00009-6>

16. Sasidharan S, Poojari R, Bahadur D, Srivastava R. Embelin-Mediated Green Synthesis of Quasi-Spherical and Star-Shaped Plasmonic Nanostructures for Antibacterial Activity, Photothermal Therapy, and Computed Tomographic Imaging. *ACS Sustainable Chemistry & Engineering*. 2018;6(8):10562-77. doi:<https://doi.org/10.1021/acssuschemeng.8b01894>
17. Lu J, Huang Y, Zhao W, Marquez RT, Meng X, Li J, et al. PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers. *Biomaterials*. 2013;34(5):1591-600. doi:<https://doi.org/10.1016/j.biomaterials.2012.10.073>
18. Husain K, Williamson TT, Nelson N, Ghansah T. Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer. *Immunological Medicine*. 2021;44(3):159-74. doi:<https://doi.org/10.1080/25785826.2020.1843267>
19. Chua MMJ, Ortega CE, Sheikh A, Lee M, Abdul-Rassoul H, Hartshorn KL, et al. CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target. *Pharmaceuticals*. 2017;10(1):18. doi:<https://doi.org/10.3390/ph10010018>
20. Anjum F, Sulaimani MN, Shafie A, Mohammad T, Ashraf GM, Bilgrami AL, et al. Bioactive phytoconstituents as potent inhibitors of casein kinase-2: dual implications in cancer and COVID-19 therapeutics. *RSC advances*. 2022;12(13):7872-82. doi:<https://doi.org/10.1039/D1RA09339H>
21. Perea SE, Baladrón I, Valenzuela C, Perera Y. CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation. *Seminars in Oncology*. 2018;45(1):58-67. doi:<https://doi.org/10.1053/j.seminoncol.2018.04.006>
22. Rosales M, Rodríguez-Ulloa A, Besada V, Ramón AC, Pérez GV, Ramos Y, et al. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945. *Cells*. 2021;10(2):338. doi:<https://doi.org/10.3390/cells10020338>
23. Sheng Z, Ge S, Gao M, Jian R, Chen X, Xu X, et al. Synthesis and Biological Activity of Embelin and its Derivatives: An Overview. *Mini-Reviews in Medicinal Chemistry*. 2020;20(5):396-407. doi:<http://dx.doi.org/10.2174/1389557519666191015202723>
24. Liang Y-H, Wu J-M, Teng J-W, Hung E, Wang H-S. Embelin downregulated cFLIP in breast cancer cell lines facilitate anti-tumor effect of IL-1 β -stimulated human umbilical cord mesenchymal stem cells. *Scientific Reports*. 2021;11(1):14720. doi:<https://doi.org/10.1038/s41598-021-94006-w>
25. Peña R, Martín P, Feresin GE, Tapia A, Machín F, Estévez-Braun A. Domino Synthesis of Embelin Derivatives with Antibacterial Activity. *Journal of Natural Products*. 2016;79(4):970-7. doi:<https://doi.org/10.1021/acs.jnatprod.5b01038>
26. Sekar M. Formulation and evaluation of antibacterial ointment containing embelin isolated from *Embelia ribes*. *International Journal of Green Pharmacy (IJGP)*. 2018;12(03). doi:<https://doi.org/10.22377/ijgp.v12i03.2020>
27. V. Ravikanth, P. Ramesh, P. V. Diwan, Y. Venkateswarlu. MICROWAVE IRRADIATION OF EMBELIN AND EVALUATION OF ANTIBACTERIAL ACTIVITY. *Heterocyclic Communications*. 2000;6(4):315-8. doi:<https://doi.org/10.1515/HC.2000.6.4.315>
28. Martín-Acosta P, Peña R, Feresin G, Tapia A, Lorenzo-Castrillejo I, Machín F, et al. Efficient Multicomponent Synthesis of Diverse Antibacterial Embelin-Privileged Structure Conjugates. *Molecules*. 2020;25(14):3290. doi:<https://doi.org/10.3390/molecules25143290>
29. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes & Diseases*. 2022. doi:<https://doi.org/10.1016/j.gendis.2022.02.007>
30. Alavi M, Nokhodchi A. Micro- and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: Recent advances and challenges. *Drug Discovery Today*. 2022;27(2):576-84. doi:<https://doi.org/10.1016/j.drudis.2021.10.007>
31. Huang Y, Lu J, Gao X, Li J, Zhao W, Sun M, et al. PEG-Derivatized Embelin as a Dual Functional Carrier for the Delivery of Paclitaxel. *Bioconjugate Chemistry*. 2012;23(7):1443-51. doi:<https://doi.org/10.1021/bc3000468>
32. Yeggoni DP, Rachamalla A, Subramanyam R. Protein stability, conformational change and binding mechanism of human serum albumin upon binding of embelin and its role in disease control. *Journal of Photochemistry and Photobiology B: Biology*. 2016;160:248-59. doi:<https://doi.org/10.1016/j.jphotobiol.2016.04.012>
33. Xu Y, Liu D, Hu J, Ding P, Chen M. Hyaluronic acid-coated pH sensitive poly (β -amino ester) nanoparticles for co-delivery of embelin and TRAIL plasmid for triple negative breast cancer treatment. *International Journal of Pharmaceutics*. 2020;573:118637. doi:<https://doi.org/10.1016/j.ijpharm.2019.118637>
34. Alavi M, Hamblin MR, Mozafari MR, Rose Alencar de Menezes I, Douglas Melo Coutinho H. Surface modification of SiO₂ nanoparticles for bacterial decontaminations of blood products. *Cellular, Molecular and Biomedical Reports*. 2022;2(2):87-97.

doi:<https://doi.org/10.55705/cmbr.2022.338888.1039>

35. Alavi M, Hamblin MR, Martinez F, Kennedy JF, Khan H. Synergistic combinations of metal, metal oxide, or metalloid nanoparticles plus antibiotics against resistant and non-resistant bacteria. *Micro Nano Bio Aspects*. 2022;1(1):1-9

36. Ni C, Zhong Y, Wu W, Song Y, Makvandi P, Yu C, et al. Co-Delivery of Nano-Silver and Vancomycin via Silica Nanopollens for Enhanced Antibacterial Functions. *Antibiotics*. 2022;11(5):685. doi:<https://doi.org/10.3390/antibiotics11050685>

37. Alavi M, Rai M, Varma RS, Hamidi M, Mozafari MR. Conventional and novel methods for the preparation of micro and nanoliposomes. *Micro Nano Bio Aspects*. 2022;1(1):18-29

38. Alavi M, Rai M, Martinez F, Kahrizi D, Khan H, Rose Alencar de Menezes I, et al. The efficiency of metal, metal oxide, and metalloid nanoparticles against cancer cells and bacterial pathogens: different mechanisms of action. *Cellular, Molecular and Biomedical Reports*. 2022;2(1):10-21. doi:<https://doi.org/10.55705/cmbr.2022.147090.1023>

39. Alavi M, Nokhodchi A. Antimicrobial and wound healing activities of electrospun nanofibers based on functionalized carbohydrates and proteins. *Cellulose*. 2022;29(3):1331-47. doi:<https://doi.org/10.1007/s10570-021-04412-6>

40. Alavi M, Rai M. Antisense RNA, the modified CRISPR-Cas9, and metal/metal oxide nanoparticles to inactivate pathogenic bacteria. *Cellular, Molecular and Biomedical Reports*. 2021;1(2):52-9. doi:<https://doi.org/10.55705/cmbr.2021.142436.1014>

41. Zhang Y, Fu S, Yang L, Qin G, Zhang E. A nano-structured TiO₂/CuO/Cu₂O coating on Ti-Cu alloy with dual function of antibacterial ability and osteogenic activity. *Journal of Materials Science & Technology*. 2022;97:201-12. doi:<https://doi.org/10.1016/j.jmst.2021.04.056>

42. Alavi M, Varma RS. Antibacterial and wound healing activities of silver nanoparticles embedded in cellulose compared to other polysaccharides and protein polymers. *Cellulose*. 2021;28(13):8295-311. doi:<https://doi.org/10.1007/s10570-021-04067-3>

43. Alavi M, Webster TJ. Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges. *Nanomedicine*. 2020;15(24):2399-410. doi:<https://doi.org/10.2217/nnm-2020-0199>

44. Liu T-M, Conde J, Lipiński T, Bednarkiewicz A, Huang C-C. Revisiting the classification of NIR-absorbing/emitting nanomaterials for in vivo bioapplications. *NPG Asia Materials*. 2016;8(8):e295-e. doi:<https://doi.org/10.1038/am.2016.106>

45. Khosravi M, Mirzaie A, Kashtali AB, Noorbazargan H. Antibacterial, anti-efflux, anti-

biofilm, anti-slime (exopolysaccharide) production and urease inhibitory efficacies of novel synthesized gold nanoparticles coated *Anthemis atopatana* extract against multidrug-resistant *Klebsiella pneumoniae* strains. *Archives of Microbiology*. 2020;202(8):2105-15. doi:<https://doi.org/10.1007/s00203-020-01930-y>

46. Parmar K, Patel J, Sheth N. Self nano-emulsifying drug delivery system for Embelin: Design, characterization and in-vitro studies. *Asian Journal of Pharmaceutical Sciences*. 2015;10(5):396-404. doi:<https://doi.org/10.1016/j.ajps.2015.04.006>

47. Mousavi SM, Babakhani S, Moradi L, Karami S, Shahbandeh M, Mirshekar M, et al. Bacteriophage as a Novel Therapeutic Weapon for Killing Colistin-Resistant Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Bacteria. *Current microbiology*. 2021;78(12):4023-36. doi:<https://doi.org/10.1007/s00284-021-02662-y>

48. Khare T, Mahalunkar S, Shriram V, Gosavi S, Kumar V. Embelin-loaded chitosan gold nanoparticles interact synergistically with ciprofloxacin by inhibiting efflux pumps in multidrug-resistant *Pseudomonas aeruginosa* and *Escherichia coli*. *Environmental Research*. 2021;199:111321. doi:<https://doi.org/10.1016/j.envres.2021.111321>

49. Sasidharan S, Bahadur D, Srivastava R, editors. Synthesis of albumin nanoparticles with a natural multi-therapeutic crosslinker - embelin. 2015 IEEE 15th International Conference on Nanotechnology (IEEE-NANO); 2015 27-30 July 2015. doi:<https://doi.org/10.1109/NANO.2015.7388932>